BIIB up +0.99% percent Today $BIIB High is at 308.65 and the Low 305.00 with current volume of 220,877.
Recent News posted below.
Biogen Idec Inc BIIB other info.
http://investorshangout.com/Biogen-Idec-Inc-BIIB-53494/
BIIB Biogen Idec Inc Recent Headline News
Strength Seen in Geron (GERN): Stock Surges 19.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - 1 hr 15 mins ago
Geron (GERN) was a big mover last session, with shares surging over 19% on the day.
BIIB: 308.41 (+2.98), GERN: 3.07 (+0.31), ILMN: 182.74 (+2.24), AFFX: 9.45 (-0.26)
Affymetrix (AFFX) Now a Strong Buy, Raised Guidance Positive - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 5:13PM CST
On Nov 14, 2014, Zacks Investment Research upgraded Affymetrix Inc. (AFFX) to a Zacks Rank #1 (Strong Buy).
BIIB: 308.41 (+2.98), ANIP: 56.47 (+2.52), AMAG: 34.98 (+0.98), AFFX: 9.45 (-0.26)
Geron Collaborates with J&J for Imetelstat - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 5:00PM CST
Geron Corporation (GERN), a clinical-stage biopharmaceutical company, announced that it has entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech, Inc., a unit of Johnson & Johnson (JNJ).
BIIB: 308.41 (+2.98), JNJ: 108.46 (+0.30), GERN: 3.07 (+0.31), AFFX: 9.45 (-0.26)
Biogen Idec Falls 3.95% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Fri Nov 14, 3:42PM CST
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $300.35 to a high of $318.02. Yesterday, the shares fell 3.9%, which took the trading range below the 3-day low of $314.33 on volume of 2.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BIIB: 308.41 (+2.98)
Biogen Idec Set to Possibly Rebound After Yesterday's Selloff of 3.95%
Comtex SmarTrend(R) - Fri Nov 14, 3:42PM CST
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $300.35 to a high of $318.02. Yesterday, the shares fell 3.9%, which took the trading range below the 3-day low of $314.33 on volume of 2.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BIIB: 308.41 (+2.98)
Isis/AstraZeneca Expand Antisense Technology Collaboration - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 3:30PM CST
Isis Pharmaceuticals (ISIS) and AstraZeneca will co-develop targeted oligonucleotide delivery methods under the expanded collaboration.
BIIB: 308.41 (+2.98), ISIS: 49.37 (+0.36), AZN: 72.18 (-0.67), SNY: 47.45 (+0.77)
Mallinckrodt Shares Down on Setback for Generic Concerta - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 2:39PM CST
Mallinckrodt (MNK) received a setback when the FDA informed the company that its methylphenidate hydrochloride extended-release tablets, USP (CII) might not be therapeutically equivalent to Johnson & Johnson's (JNJ) Concerta.
MNK: 88.91 (+0.80), BIIB: 308.41 (+2.98), JNJ: 108.46 (+0.30), ACT: 253.47 (+9.70)
Stocks Drift Lower As Biotechs Tumble
at Investor's Business Daily - Fri Nov 14, 1:48PM CST
Stocks drifted mostly lower Friday with a little more than one hour left in the session, with medical stocks leading the way down. Volume in the stock market today was running lighter than Thursday's levels. The Nasdaq rose less than 0.1%, the S&P...
BIIB: 308.41 (+2.98), NTES: 100.92 (+0.28), HAL: 51.13 (-3.95), BITA: 90.66 (-1.25), BHI: 67.27 (+7.38), CELG: 105.61 (+1.56)
Stocks Mixed; Amazon Jumps On Book Deal
at Investor's Business Daily - Fri Nov 14, 12:32PM CST
Stocks were mixed, but gained a small amount of ground in afternoon trading Friday. A better-than-expected retail sales report lifted Wall Street spirits in the stock market today. The Nasdaq gained 0.1%; the Dow Jones industrial average dropped...
BIIB: 308.41 (+2.98), AMZN: 323.40 (-4.42), HAL: 51.15 (-3.93), ILMN: 182.74 (+2.24), BITA: 90.66 (-1.25), BHI: 67.27 (+7.38), CELG: 105.61 (+1.56)
Biotech off today led by Biogen
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 11:00AM CST
BIIB: 308.41 (+2.98), VRTX: 112.08 (+0.74), GILD: 101.52 (-0.54), ALXN: 191.29 (+2.53), AMGN: 160.11 (+2.43), IBB: 292.33 (+4.16), REGN: 406.85 (+11.65), CELG: 105.61 (+1.56)
Insider Trading Alert - RP, RLGY And BIIB Traded By Insiders
at The Street - Thu Nov 13, 10:15AM CST
Stocks with insider trader activity include RP, RLGY and BIIB
BIIB: 308.41 (+2.98), RLGY: 42.88 (-0.09), RP: 21.70 (-0.28)
Alnylam Adds Hepatic Infectious Disease Drugs to Pipeline - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 4:40PM CST
Alnylam (ALNY) expands its hepatic infectious disease pipeline with two new candidates, ALN-HDV (hepatitis delta viral) and ALN-PDL (chronic liver).
BIIB: 308.41 (+2.98), ALNY: 90.98 (+0.86), ILMN: 182.74 (+2.24), AMAG: 34.98 (+0.98)
PharmaPoint: Hemophilia A and B - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update Report
M2 - Wed Nov 12, 5:41AM CST
Research and Markets (http://www.researchandmarkets.com/research/5kjfp3/pharmapoint) has announced the addition of the "PharmaPoint: Hemophilia A and B - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update" report to their offering. The competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of recombinant FVIII and FIX replacement factors, and patients with severe forms of the disease receive frequent prophylactic infusions beginning from the first one or two years of life and often continuing through adulthood. However, the burden on patients and their families to maintain the prophylactic treatment schedule is high, and there is a significant unmet need for new therapies that can reduce the number of weekly prophylactic infusions and alleviate some of this treatment burden. Several pharmaceutical companies, including Biogen Idec, Novo Nordisk, Bayer, Baxter and CSL Behring, will be launching long-acting rFVIII and rFIX therapies that aim to address this unmet need by providing increased protein half-life that potentially extends the time between prophylactic doses. The emergence of these new products, beginning in 2014 in the US and 2015 in the 5EU, will have a drastic effect on the hemophilia A and B treatment landscapes in the 7MM as patients adopt these premium-priced products. This sea change will be lead by Biogen Idec's Alprolix and Eloctate, which launched in the US in March and June 2014. Key Questions Answered - How will the launch of long-acting rFVIII and rFIX replacement products affect the hemophilia A and B recombinant treatment landscape? How will Biogen Idec's pricing strategy impact market growth? - How will launch timing of the long-acting products affect patient adoption over the forecast period? - The unmet needs of hemophilia A and B patients in the US and 5EU are relatively low. What unmet needs will remain after the launch of the long-acting factors? - How will increasing cost consciousness among European reimbursement authorities affect market growth in the 5EU? - The level of unmet needs for hemophilia patients in the developing markets of Argentina and China are higher compared to the established markets. Will the launch of long-acting products affect these markets? What additional opportunity will remain during the forecast period? Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Disease Management 6 Competitive Assessment 7 Opportunity and Unmet Need 8 Pipeline Assessment 9 Current and Future Players 10 Market Outlook 11 Appendix Companies Mentioned - Baxter - Biogen Idec - Novo Nordisk - CSL Behring - Bayer - Pfizer For more information visit http://www.researchandmarkets.com/research/5k...harmapoint
BIIB: 308.41 (+2.98), NVO: 43.89 (-0.24)
Hemophilia A and B - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update New Report Launched
M2 - Wed Nov 12, 3:38AM CST
Market Research Reports, Inc. has announced the addition of "PharmaPoint: Hemophilia A and B - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update" research report to their website http://www.MarketResearchReports.com
BIIB: 308.41 (+2.98)
Dynavax's Heplisav Phase III Trial Recommended to Continue - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 4:30PM CST
Positive news flowed in for Dynavax Technologies Corporation (DVAX) when the company announced that the independent Data and Safety Monitoring Board (DSMB) completed its first prespecified review of the ongoing phase III trial on Heplisav.
CYTK: 4.31 (+0.08), DVAX: 14.44 (-0.24), BIIB: 308.41 (+2.98)
Aegerion to Acquire Myalept, Boost Portfolio - Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 11:52AM CST
Aegerion Pharmaceuticals, Inc. (AEGR) has signed an agreement with AstraZeneca to acquire the latter's Myalept for $325 million.
BIIB: 308.41 (+2.98), AZN: 72.18 (-0.67), LLY: 67.23 (-0.10), AEGR: 20.12 (+0.46), GSK: 46.01 (+0.27)
Stock Market News for November 11, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 9:10AM CST
Benchmarks posted modest gains on Monday, boosted by a rally in healthcare and transportation stocks
NFLX: 388.19 (+2.15), YHOO: 51.47 (-0.28), AMZN: 323.40 (-4.42), BIIB: 308.41 (+2.98), VRTX: 112.08 (+0.74), FEYE: 33.33 (-0.47), LNKD: 226.83 (-7.06), EBAY: 54.80 (+0.44), GILD: 101.53 (-0.53), AMGN: 160.11 (+2.43), ABBV: 65.07 (+1.07), REGN: 406.85 (+11.65), CELG: 105.61 (+1.56)
Orexigen (OREX) Worth Watching: Stock Soars 33.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 8:25AM CST
Orexigen (OREX) was a big mover last session, with shares surging over 33% on the day.
BIIB: 308.41 (+2.98), OREX: 5.61 (-0.04), AMAG: 34.98 (+0.98), AFFX: 9.45 (-0.26)
Osiris Therapeutics Beats on Q3 Earnings & Revenues - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Nov 11, 8:00AM CST
Osiris Therapeutics (OSIR) performed well above expectations with revenues increasing significantly.
CYTK: 4.31 (+0.08), BIIB: 308.41 (+2.98), OSIR: 13.37 (+0.32), AMAG: 34.98 (+0.98)
Repros Soars on Positive FDA Meeting Regarding Androxa - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 4:20PM CST
Shares of Repros Therapeutics (RPRX) shot up 56.9% following a successful meeting with the FDA regarding Androxal.
BIIB: 308.41 (+2.98), RPRX: 9.40 (+0.06), ABBV: 65.07 (+1.07), AMAG: 34.98 (+0.98)
Recent News posted below.
Biogen Idec Inc BIIB other info.
http://investorshangout.com/Biogen-Idec-Inc-BIIB-53494/
BIIB Biogen Idec Inc Recent Headline News
Strength Seen in Geron (GERN): Stock Surges 19.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - 1 hr 15 mins ago
Geron (GERN) was a big mover last session, with shares surging over 19% on the day.
BIIB: 308.41 (+2.98), GERN: 3.07 (+0.31), ILMN: 182.74 (+2.24), AFFX: 9.45 (-0.26)
Affymetrix (AFFX) Now a Strong Buy, Raised Guidance Positive - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 5:13PM CST
On Nov 14, 2014, Zacks Investment Research upgraded Affymetrix Inc. (AFFX) to a Zacks Rank #1 (Strong Buy).
BIIB: 308.41 (+2.98), ANIP: 56.47 (+2.52), AMAG: 34.98 (+0.98), AFFX: 9.45 (-0.26)
Geron Collaborates with J&J for Imetelstat - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 5:00PM CST
Geron Corporation (GERN), a clinical-stage biopharmaceutical company, announced that it has entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech, Inc., a unit of Johnson & Johnson (JNJ).
BIIB: 308.41 (+2.98), JNJ: 108.46 (+0.30), GERN: 3.07 (+0.31), AFFX: 9.45 (-0.26)
Biogen Idec Falls 3.95% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Fri Nov 14, 3:42PM CST
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $300.35 to a high of $318.02. Yesterday, the shares fell 3.9%, which took the trading range below the 3-day low of $314.33 on volume of 2.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BIIB: 308.41 (+2.98)
Biogen Idec Set to Possibly Rebound After Yesterday's Selloff of 3.95%
Comtex SmarTrend(R) - Fri Nov 14, 3:42PM CST
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $300.35 to a high of $318.02. Yesterday, the shares fell 3.9%, which took the trading range below the 3-day low of $314.33 on volume of 2.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
BIIB: 308.41 (+2.98)
Isis/AstraZeneca Expand Antisense Technology Collaboration - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 3:30PM CST
Isis Pharmaceuticals (ISIS) and AstraZeneca will co-develop targeted oligonucleotide delivery methods under the expanded collaboration.
BIIB: 308.41 (+2.98), ISIS: 49.37 (+0.36), AZN: 72.18 (-0.67), SNY: 47.45 (+0.77)
Mallinckrodt Shares Down on Setback for Generic Concerta - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 2:39PM CST
Mallinckrodt (MNK) received a setback when the FDA informed the company that its methylphenidate hydrochloride extended-release tablets, USP (CII) might not be therapeutically equivalent to Johnson & Johnson's (JNJ) Concerta.
MNK: 88.91 (+0.80), BIIB: 308.41 (+2.98), JNJ: 108.46 (+0.30), ACT: 253.47 (+9.70)
Stocks Drift Lower As Biotechs Tumble
at Investor's Business Daily - Fri Nov 14, 1:48PM CST
Stocks drifted mostly lower Friday with a little more than one hour left in the session, with medical stocks leading the way down. Volume in the stock market today was running lighter than Thursday's levels. The Nasdaq rose less than 0.1%, the S&P...
BIIB: 308.41 (+2.98), NTES: 100.92 (+0.28), HAL: 51.13 (-3.95), BITA: 90.66 (-1.25), BHI: 67.27 (+7.38), CELG: 105.61 (+1.56)
Stocks Mixed; Amazon Jumps On Book Deal
at Investor's Business Daily - Fri Nov 14, 12:32PM CST
Stocks were mixed, but gained a small amount of ground in afternoon trading Friday. A better-than-expected retail sales report lifted Wall Street spirits in the stock market today. The Nasdaq gained 0.1%; the Dow Jones industrial average dropped...
BIIB: 308.41 (+2.98), AMZN: 323.40 (-4.42), HAL: 51.15 (-3.93), ILMN: 182.74 (+2.24), BITA: 90.66 (-1.25), BHI: 67.27 (+7.38), CELG: 105.61 (+1.56)
Biotech off today led by Biogen
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 11:00AM CST
BIIB: 308.41 (+2.98), VRTX: 112.08 (+0.74), GILD: 101.52 (-0.54), ALXN: 191.29 (+2.53), AMGN: 160.11 (+2.43), IBB: 292.33 (+4.16), REGN: 406.85 (+11.65), CELG: 105.61 (+1.56)
Insider Trading Alert - RP, RLGY And BIIB Traded By Insiders
at The Street - Thu Nov 13, 10:15AM CST
Stocks with insider trader activity include RP, RLGY and BIIB
BIIB: 308.41 (+2.98), RLGY: 42.88 (-0.09), RP: 21.70 (-0.28)
Alnylam Adds Hepatic Infectious Disease Drugs to Pipeline - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 4:40PM CST
Alnylam (ALNY) expands its hepatic infectious disease pipeline with two new candidates, ALN-HDV (hepatitis delta viral) and ALN-PDL (chronic liver).
BIIB: 308.41 (+2.98), ALNY: 90.98 (+0.86), ILMN: 182.74 (+2.24), AMAG: 34.98 (+0.98)
PharmaPoint: Hemophilia A and B - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update Report
M2 - Wed Nov 12, 5:41AM CST
Research and Markets (http://www.researchandmarkets.com/research/5kjfp3/pharmapoint) has announced the addition of the "PharmaPoint: Hemophilia A and B - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update" report to their offering. The competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of recombinant FVIII and FIX replacement factors, and patients with severe forms of the disease receive frequent prophylactic infusions beginning from the first one or two years of life and often continuing through adulthood. However, the burden on patients and their families to maintain the prophylactic treatment schedule is high, and there is a significant unmet need for new therapies that can reduce the number of weekly prophylactic infusions and alleviate some of this treatment burden. Several pharmaceutical companies, including Biogen Idec, Novo Nordisk, Bayer, Baxter and CSL Behring, will be launching long-acting rFVIII and rFIX therapies that aim to address this unmet need by providing increased protein half-life that potentially extends the time between prophylactic doses. The emergence of these new products, beginning in 2014 in the US and 2015 in the 5EU, will have a drastic effect on the hemophilia A and B treatment landscapes in the 7MM as patients adopt these premium-priced products. This sea change will be lead by Biogen Idec's Alprolix and Eloctate, which launched in the US in March and June 2014. Key Questions Answered - How will the launch of long-acting rFVIII and rFIX replacement products affect the hemophilia A and B recombinant treatment landscape? How will Biogen Idec's pricing strategy impact market growth? - How will launch timing of the long-acting products affect patient adoption over the forecast period? - The unmet needs of hemophilia A and B patients in the US and 5EU are relatively low. What unmet needs will remain after the launch of the long-acting factors? - How will increasing cost consciousness among European reimbursement authorities affect market growth in the 5EU? - The level of unmet needs for hemophilia patients in the developing markets of Argentina and China are higher compared to the established markets. Will the launch of long-acting products affect these markets? What additional opportunity will remain during the forecast period? Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Disease Management 6 Competitive Assessment 7 Opportunity and Unmet Need 8 Pipeline Assessment 9 Current and Future Players 10 Market Outlook 11 Appendix Companies Mentioned - Baxter - Biogen Idec - Novo Nordisk - CSL Behring - Bayer - Pfizer For more information visit http://www.researchandmarkets.com/research/5k...harmapoint
BIIB: 308.41 (+2.98), NVO: 43.89 (-0.24)
Hemophilia A and B - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update New Report Launched
M2 - Wed Nov 12, 3:38AM CST
Market Research Reports, Inc. has announced the addition of "PharmaPoint: Hemophilia A and B - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update" research report to their website http://www.MarketResearchReports.com
BIIB: 308.41 (+2.98)
Dynavax's Heplisav Phase III Trial Recommended to Continue - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 4:30PM CST
Positive news flowed in for Dynavax Technologies Corporation (DVAX) when the company announced that the independent Data and Safety Monitoring Board (DSMB) completed its first prespecified review of the ongoing phase III trial on Heplisav.
CYTK: 4.31 (+0.08), DVAX: 14.44 (-0.24), BIIB: 308.41 (+2.98)
Aegerion to Acquire Myalept, Boost Portfolio - Shares Up - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 11:52AM CST
Aegerion Pharmaceuticals, Inc. (AEGR) has signed an agreement with AstraZeneca to acquire the latter's Myalept for $325 million.
BIIB: 308.41 (+2.98), AZN: 72.18 (-0.67), LLY: 67.23 (-0.10), AEGR: 20.12 (+0.46), GSK: 46.01 (+0.27)
Stock Market News for November 11, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 9:10AM CST
Benchmarks posted modest gains on Monday, boosted by a rally in healthcare and transportation stocks
NFLX: 388.19 (+2.15), YHOO: 51.47 (-0.28), AMZN: 323.40 (-4.42), BIIB: 308.41 (+2.98), VRTX: 112.08 (+0.74), FEYE: 33.33 (-0.47), LNKD: 226.83 (-7.06), EBAY: 54.80 (+0.44), GILD: 101.53 (-0.53), AMGN: 160.11 (+2.43), ABBV: 65.07 (+1.07), REGN: 406.85 (+11.65), CELG: 105.61 (+1.56)
Orexigen (OREX) Worth Watching: Stock Soars 33.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 8:25AM CST
Orexigen (OREX) was a big mover last session, with shares surging over 33% on the day.
BIIB: 308.41 (+2.98), OREX: 5.61 (-0.04), AMAG: 34.98 (+0.98), AFFX: 9.45 (-0.26)
Osiris Therapeutics Beats on Q3 Earnings & Revenues - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Nov 11, 8:00AM CST
Osiris Therapeutics (OSIR) performed well above expectations with revenues increasing significantly.
CYTK: 4.31 (+0.08), BIIB: 308.41 (+2.98), OSIR: 13.37 (+0.32), AMAG: 34.98 (+0.98)
Repros Soars on Positive FDA Meeting Regarding Androxa - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 4:20PM CST
Shares of Repros Therapeutics (RPRX) shot up 56.9% following a successful meeting with the FDA regarding Androxal.
BIIB: 308.41 (+2.98), RPRX: 9.40 (+0.06), ABBV: 65.07 (+1.07), AMAG: 34.98 (+0.98)
